- Home
- SVA vs BNGO Comparison
SVA vs BNGO Comparison
Compare SVA & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVA
- BNGO
- Stock Information
- Founded
- SVA N/A
- BNGO 2003
- Country
- SVA
- BNGO United States
- Employees
- SVA 3261
- BNGO N/A
- Industry
- SVA
- BNGO Biotechnology: Laboratory Analytical Instruments
- Sector
- SVA
- BNGO Industrials
- Exchange
- SVA NYSE
- BNGO Nasdaq
- Market Cap
- SVA N/A
- BNGO 38.1M
- IPO Year
- SVA N/A
- BNGO 2018
- Fundamental
- Price
- SVA $6.47
- BNGO $0.44
- Analyst Decision
- SVA
- BNGO Buy
- Analyst Count
- SVA 0
- BNGO 3
- Target Price
- SVA N/A
- BNGO $1.50
- AVG Volume (30 Days)
- SVA N/A
- BNGO 1.5M
- Earning Date
- SVA N/A
- BNGO 08-07-2024
- Dividend Yield
- SVA N/A
- BNGO N/A
- EPS Growth
- SVA N/A
- BNGO N/A
- EPS
- SVA N/A
- BNGO N/A
- Revenue
- SVA N/A
- BNGO $36,579,000.00
- Revenue This Year
- SVA N/A
- BNGO $5.22
- Revenue Next Year
- SVA N/A
- BNGO $26.92
- P/E Ratio
- SVA N/A
- BNGO N/A
- Revenue Growth
- SVA N/A
- BNGO 16.08
- 52 Week Low
- SVA N/A
- BNGO $0.31
- 52 Week High
- SVA N/A
- BNGO $3.85
- Technical
- Relative Strength Index (RSI)
- SVA N/A
- BNGO 38.07
- Support Level
- SVA N/A
- BNGO $0.49
- Resistance Level
- SVA N/A
- BNGO $0.56
- Average True Range (ATR)
- SVA 0.00
- BNGO 0.04
- MACD
- SVA 0.00
- BNGO -0.00
- Stochastic Oscillator
- SVA 0.00
- BNGO 8.02
About SVA SINOVAC BIOTECH LTD
Sinovac Biotech Ltd is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease (HFMD) caused by EV71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps.
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.